DelMar Pharmaceuticals Company Profile (NASDAQ:DMPI)

About DelMar Pharmaceuticals (NASDAQ:DMPI)

DelMar Pharmaceuticals logoDelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Shell Companies
  • Sub-Industry: N/A
  • Symbol: NASDAQ:DMPI
  • CUSIP: N/A
  • Web:
  • Market Cap: $19.4 million
  • Outstanding Shares: 21,551,000
Average Prices:
  • 50 Day Moving Avg: $1.06
  • 200 Day Moving Avg: $2.01
  • 52 Week Range: $0.80 - $5.77
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.58
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.01 per share
  • Price / Book: 93.00
  • EBITDA: ($8,300,000.00)
  • Return on Assets: -171.21%
  • Current Ratio: 6.05%
  • Quick Ratio: 6.05%
  • Average Volume: 959,519 shs.
  • Beta: 0.86
  • Short Ratio: 0.66

Frequently Asked Questions for DelMar Pharmaceuticals (NASDAQ:DMPI)

What is DelMar Pharmaceuticals' stock symbol?

DelMar Pharmaceuticals trades on the NASDAQ under the ticker symbol "DMPI."

When did DelMar Pharmaceuticals' stock split? How did DelMar Pharmaceuticals' stock split work?

DelMar Pharmaceuticals's stock reverse split on Friday, May 20th 2016. The 1-4 reverse split was announced on Thursday, May 19th 2016. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 19th 2016. An investor that had 100 shares of DelMar Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

How were DelMar Pharmaceuticals' earnings last quarter?

DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) posted its quarterly earnings results on Thursday, May, 18th. The company reported ($0.18) EPS for the quarter, hitting analysts' consensus estimates of ($0.18). View DelMar Pharmaceuticals' Earnings History.

Where is DelMar Pharmaceuticals' stock going? Where will DelMar Pharmaceuticals' stock price be in 2017?

4 brokerages have issued 1-year price targets for DelMar Pharmaceuticals' shares. Their predictions range from $11.00 to $16.00. On average, they expect DelMar Pharmaceuticals' stock price to reach $13.00 in the next twelve months. View Analyst Ratings for DelMar Pharmaceuticals.

What are analysts saying about DelMar Pharmaceuticals stock?

Here are some recent quotes from research analysts about DelMar Pharmaceuticals stock:

  • 1. HC Wainwright analysts commented, "Ovarian Cancer Role for VAL-083; Reiterate Buy Stock Data 10/13/2017 Price $0.88 Exchange NASDAQ Price Target $12.00 52-Week High $5.77 52-Week Low $0.80 Enterprise Value (M) $12.4 Market Cap (M) $19 Public Market Float (M) 19.3 Shares Outstanding (M) 21.6 3 Month Avg Volume 959,521 Short Interest (M) 0.35 Balance Sheet Metrics Cash (M) $6.59 Total Debt (M) $0.00 Total Cash/Share $0.31 Book Value/Share $(0.09) EPS Diluted Full Year – Jun 2016A 2017A 2018E 1Q (0.15) (0.23) (0.17) 2Q (0.24) (0.13) (0.16) 3Q (0.10) (0.18) (0.14) 4Q (0.31) (0.20) (0.12) FY (0.81) (0.74) (0.57) 6 5 4 3 2 1 0 OCT- 16 FEB- 17 J UN- 17 OCT- 17 40 30 20 10 0 Vol. (mil) Price Continuing coverage under the name H.C. Wainwright & Co. with a Buy rating. Effective October 5, 2017, research in the above titled name will now be published under H.C. Wainwright & Co. and no longer distributed in conjunction with ‘Rodman & Renshaw, a unit of H.C." (10/16/2017)
  • 2. Maxim Group analysts commented, "Delmar announced news of another Phase II trial (biomarker driven), N=20-30 in newly diagnosed MGMT-unmethylated glioblastoma multiforme (GBM). The trial will be funded by Guangxi Wuzhou Pharmaceutical Group Co. (private). Management states that data is expected 9-15 months from the time the trial begins." (9/11/2017)

Who are some of DelMar Pharmaceuticals' key competitors?

Who are DelMar Pharmaceuticals' key executives?

DelMar Pharmaceuticals' management team includes the folowing people:

  • Erich Mohr Ph.D., Chairman of the Board
  • Jeffrey A. Bacha, President, Chief Executive Officer, Director
  • Scott Praill, Chief Financial Officer
  • Dennis M. Brown Ph.D., Chief Scientific Officer, Director
  • John K. Bell, Lead Independent Director
  • Saiid Zarrabian, Director
  • Lynda Sarah Cranston, Independent Director
  • Robert J. Toth Jr., Independent Director

Who owns DelMar Pharmaceuticals stock?

DelMar Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include INTRACOASTAL CAPITAL, LLC (4.99%). Company insiders that own DelMar Pharmaceuticals stock include Jeffrey Bacha, John K Bell and Scott Praill. View Institutional Ownership Trends for DelMar Pharmaceuticals.

How do I buy DelMar Pharmaceuticals stock?

Shares of DelMar Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DelMar Pharmaceuticals' stock price today?

One share of DelMar Pharmaceuticals stock can currently be purchased for approximately $0.93.

MarketBeat Community Rating for DelMar Pharmaceuticals (NASDAQ DMPI)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  84 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  122
MarketBeat's community ratings are surveys of what our community members think about DelMar Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for DelMar Pharmaceuticals (NASDAQ:DMPI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $13.00 (1,297.85% upside)
Consensus Price Target History for DelMar Pharmaceuticals (NASDAQ:DMPI)
Price Target History for DelMar Pharmaceuticals (NASDAQ:DMPI)
Analysts' Ratings History for DelMar Pharmaceuticals (NASDAQ:DMPI)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017HC WainwrightSet Price TargetBuy$12.00N/AView Rating Details
9/11/2017Maxim GroupReiterated RatingHoldHighView Rating Details
8/8/2017Dawson JamesReiterated RatingBuyHighView Rating Details
1/5/2017AegisInitiated CoverageBuy$16.00N/AView Rating Details
7/18/2016Rodman & RenshawReiterated RatingBuyN/AView Rating Details
2/18/2016Roth CapitalInitiated CoverageBuyN/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for DelMar Pharmaceuticals (NASDAQ:DMPI)
Earnings by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)
Earnings History by Quarter for DelMar Pharmaceuticals (NASDAQ DMPI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/18/2017($0.18)($0.18)ViewN/AView Earnings Details
2/10/201712/31/2016($0.22)($0.13)ViewN/AView Earnings Details
11/10/20169/30/2016($0.15)($0.23)ViewN/AView Earnings Details
5/13/2016($0.05)($0.03)ViewN/AView Earnings Details
2/16/2016Q2 16($0.03)($0.06)ViewN/AView Earnings Details
9/4/2015Q4 2015($0.09)($0.02)ViewN/AView Earnings Details
5/15/2015Q3 2015($0.07)($0.04)ViewN/AView Earnings Details
2/12/2015Q2 2015($0.06)($0.03)ViewN/AView Earnings Details
11/10/2014Q1 2015($0.07)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for DelMar Pharmaceuticals (NASDAQ:DMPI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20172($0.27)($0.19)($0.23)
Q3 20172($0.28)($0.16)($0.22)
Q4 20172($0.55)($0.36)($0.46)
(Data provided by Zacks Investment Research)


Dividend History for DelMar Pharmaceuticals (NASDAQ:DMPI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for DelMar Pharmaceuticals (NASDAQ:DMPI)
Institutional Ownership Percentage: 8.64%
Insider Trades by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)
Institutional Ownership by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)
Insider Trades by Quarter for DelMar Pharmaceuticals (NASDAQ:DMPI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/6/2017Jeffrey BachaCEOBuy10,000$0.87$8,700.00View SEC Filing  
10/5/2017Scott PraillInsiderBuy17,500$0.85$14,875.00View SEC Filing  
6/26/2017Jeffrey BachaCEOBuy6,700$3.60$24,120.00View SEC Filing  
6/26/2017John K BellDirectorBuy4,167$3.60$15,001.20View SEC Filing  
6/6/2017Jeffrey BachaCEOBuy5,000$2.12$10,600.00View SEC Filing  
6/6/2017John K BellDirectorBuy10,000$2.12$21,200.00View SEC Filing  
6/6/2017Scott PraillCFOBuy9,500$2.10$19,950.00View SEC Filing  
5/5/2017Jeffrey BachaCEOBuy2,500$2.20$5,500.00View SEC Filing  
2/1/2017Jeffrey BachaCEOBuy4,000$5.00$20,000.00View SEC Filing  
11/25/2015Jeffrey BachaCEOBuy7,500$1.47$11,025.00View SEC Filing  
10/8/2015Jeffrey BachaCEOBuy3,000$0.80$2,400.00View SEC Filing  
9/18/2015Jeffrey BachaCEOBuy4,000$0.83$3,320.00View SEC Filing  
7/22/2015Dennis M BrownMajor ShareholderBuy75,000$0.60$45,000.00View SEC Filing  
7/16/2015Jeffrey BachaCEOBuy50,000$0.60$30,000.00View SEC Filing  
7/16/2015William J GarnerDirectorBuy16,666$0.60$9,999.60View SEC Filing  
1/22/2015Jeffrey BachaCEOBuy7,500$0.66$4,950.00View SEC Filing  
12/9/2014Jeffrey BachaCEOBuy2,500$0.90$2,250.00View SEC Filing  
11/26/2014Jeffrey BachaCEOBuy2,500$0.92$2,300.00View SEC Filing  
11/21/2014John K BellDirectorBuy8,000$0.95$7,600.00View SEC Filing  
9/18/2014Jeffrey BachaCEOBuy4,000$0.98$3,920.00View SEC Filing  
9/15/2014Jeffrey BachaCEOBuy4,985$0.75$3,738.75View SEC Filing  
9/8/2014John K BellDirectorBuy7,000$0.71$4,970.00View SEC Filing  
9/4/2014John K BellDirectorBuy8,000$0.78$6,240.00View SEC Filing  
4/22/2014John K BellDirectorBuy20,000$1.25$25,000.00View SEC Filing  
3/18/2014Dennis M BrownMajor ShareholderBuy10,000$1.30$13,000.00View SEC Filing  
3/18/2014Robert Joseph Toth JrDirectorBuy25,000$1.30$32,500.00View SEC Filing  
3/4/2014Dennis M BrownMajor ShareholderBuy5,000$1.56$7,800.00View SEC Filing  
2/21/2014Jeffrey BachaCEOBuy5,000$1.00$5,000.00View SEC Filing  
2/13/2014Jeffrey BachaCEOBuy5,000$0.80$4,000.00View SEC Filing  
2/11/2014John K BellDirectorBuy9,000$0.83$7,470.00View SEC Filing  
2/5/2014Robert Joseph Toth JrDirectorBuy9,000$0.88$7,920.00View SEC Filing  
1/31/2014Robert Joseph Toth JrDirectorBuy2,000$0.87$1,740.00View SEC Filing  
1/29/2014Robert Joseph Toth JrDirectorBuy7,500$0.91$6,825.00View SEC Filing  
9/20/2013William J GarnerDirectorBuy5,000$1.00$5,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for DelMar Pharmaceuticals (NASDAQ:DMPI)
Latest Headlines for DelMar Pharmaceuticals (NASDAQ:DMPI)
DateHeadline logoIs Now The Right Time To Invest In Healthcare And DelMar Pharmaceuticals Inc (DMPI)? - October 17 at 6:44 PM logoSeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) - October 10 at 3:40 PM logoDelMar Pharmaceuticals, Inc. (DMPI) Insider Buys $14,875.00 in Stock - October 5 at 10:28 PM logoHC Wainwright Reaffirms Buy Rating for DelMar Pharmaceuticals, Inc. (DMPI) - October 5 at 3:38 PM logoEarnings Review and Free Research Report: DelMar Missed Earnings Expectations - October 5 at 10:16 AM logoInvestor Network: DelMar Pharmaceuticals, Inc. to Host Earnings Call - October 4 at 4:40 PM logoDelMar Pharmaceuticals Presents Poster at AACR's Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer - October 3 at 8:49 AM logoDelMar Pharmaceuticals Announces Closing Of $10 Million Registered Direct Offering Priced At-The-Market - September 22 at 4:59 PM logoToday's Research Reports on Trending Tickers: DelMar Pharmaceuticals and Ionis Pharmaceuticals - September 21 at 9:24 AM logoDelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083 - September 20 at 6:46 PM logoDelMar Pharmaceuticals Announces $10 Million Registered Direct Offering Priced At-The-Market - September 20 at 6:46 PM logoDelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer - September 18 at 3:20 PM logoDelMar Pharmaceuticals (DMPI) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow - September 14 at 5:33 AM logoDelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme - September 11 at 6:35 PM logoDelMar Pharmaceuticals, Inc. (DMPI) Earns Hold Rating from Maxim Group - September 11 at 1:22 PM logoDelMar Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 10-12, 2017 - September 6 at 5:53 PM logoDelMar Pharmaceuticals, Inc. (DMPI) Expected to Post Earnings of -$0.25 Per Share - August 27 at 2:24 PM logoDelMar Pharmaceuticals, Inc. (DMPI) Set to Announce Quarterly Earnings on Thursday - August 24 at 1:14 AM logoDawson James Reaffirms "Buy" Rating for DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) - August 15 at 7:40 AM logoDelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) Downgraded by Maxim Group - August 14 at 2:30 PM logoDelMar Pharmaceuticals - The $2 Biotech Stock That Could Win Brain Cancer Fight - August 1 at 6:35 PM logoDelMar Pharmaceuticals Receives Approval from China's Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM - July 24 at 10:33 AM logoExclusive: DelMar Pharma CEO Sheds Light On Glioblastoma, And How Its Drug Could Help Sen. John McCain - July 22 at 12:50 AM logoDelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) Expected to Announce Earnings of -$0.25 Per Share - July 20 at 12:27 AM logoDelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM - July 18 at 7:31 PM logoBRIEF-Delmar formalizes collaboration with PRA Health Sciences for phase 3 trial of val-083 - May 12 at 10:20 PM logoDelmar Pharma (DMPI) Provides VAL-083 Updates from AACR Meeting - - April 7 at 4:46 PM logoDelmar Pharma (DMPI) Announces Abstract Presentations for AACR - - March 29 at 8:21 PM logoDelmar Pharma (DMPI) Doses First Patient in Phase Two Trial of VAL-083 for MGMT-unmethylated Recurrent GBM - February 13 at 5:29 PM logoDelmar Pharma (DMPI), MD Anderson Initiate New Phase Two Trial of VAL-083 for MGMT-unmethylated Recurrent GBM - January 26 at 3:58 AM logoDelMar Pharmaceuticals and MD Anderson Initiate New Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM) - January 25 at 5:57 PM logoDelMar Pharmaceuticals Receives Notice of Allowance from the US Patent and Trademark Office for Key Patent for VAL-083 - December 14 at 5:48 PM logo8:12 am DelMar Pharma receives a Notice of Allowance from the USPTO for patent entitled, 'Improved Analytical Methods for Analyzing and Determining Impurities in Dianhydrogalactitol' - December 14 at 5:48 PM logoDMPI: Three New Clinical Trials with VAL-083 will be Initiated - November 29 at 5:42 PM logoDELMAR PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events - February 18 at 10:57 AM logoEARNINGS SUMMARY: Details of DelMar Pharmaceuticals Inc. Q2 Earnings Report - February 16 at 12:17 PM logoDelMar Pharmaceuticals Inc. Bottom Line Rises 327% In Q2 - February 16 at 12:17 PM logoDELMAR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report - February 12 at 4:25 PM



DelMar Pharmaceuticals (DMPI) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.